Editas Medicine Revenue and Competitors

Boston, MA USA

Location

$656.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Editas Medicine's estimated annual revenue is currently $24.5M per year.(i)
  • Editas Medicine received $50.0M in venture funding in December 2017.
  • Editas Medicine's estimated revenue per employee is $90,369
  • Editas Medicine's total funding is $656.6M.
  • Editas Medicine's current valuation is $1.5B. (January 2022)

Employee Data

  • Editas Medicine has 271 Employees.(i)
  • Editas Medicine grew their employee count by -5% last year.

Editas Medicine's People

NameTitleEmail/Phone
1
VP, Process and Analytical DevelopmentReveal Email/Phone
2
VP Financial Planning AnalysisReveal Email/Phone
3
VP, Intellectual PropertyReveal Email/Phone
4
SVPReveal Email/Phone
5
EVP, CTO and CBOReveal Email/Phone
6
VP, Head Genetics and GenomicsReveal Email/Phone
7
Head In Vivo Regulatory AffairsReveal Email/Phone
8
SVP Operations Editas MedicinesReveal Email/Phone
9
VP Finance and Corporate ControllerReveal Email/Phone
10
VP, Associate General Counsel and Asst. SecretaryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$92.1M5010%$127MN/A
Add Company

What Is Editas Medicine?

Unlocking the Promise of Genome Editing to Deliver Life-Changing Medicines. As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$656.6M

Total Funding

271

Number of Employees

$24.5M

Revenue (est)

-5%

Employee Growth %

$1.5B

Valuation

N/A

Accelerator

Editas Medicine News

2022-04-17 - Editas Medicine Gets FDA Rare Pediatric Disease Designation for EDIT-301

Editas Medicine Inc. said the U.S. Food and Drug Administration granted rare pediatric disease designation to EDIT-301, an investigational,...

2022-04-17 - Editas' gene editing beta thalassemia drug wins pediatric ...

Amid chaos comes good news—Editas Medicine has received Rare Pediatric Disease designation from the FDA for its gene-edited medicine EDIT-301 to treat...

2022-04-17 - Editas Medicine Receives FDA Rare Pediatric Disease ...

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced...

2019-01-22 - Editas Medicine CEO steps down as company moves into product development stage

Editas’s stock fell more than 20 percent on the Nasdaq Tuesday morning following the announcement. The news dragged other gene-editing shares down as well. Switzerland-based Crispr Therapeutics’ shares, which also trade on the Nasdaq, fell more than 13 percent, while Cambridge-based Intellia The ...

2018-12-28 - Andrew Hack to Join Bain Capital as a Managing Director

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) — Editas Medicine, Inc.(NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D., Ph.D., will be stepping down from the Company, effective March 1, 2019, to return to the investment indus ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$79.8M275-1%$3M
#2
$81.7M275-18%N/A
#3
$62.8M27847%$240.8M
#4
$15M28131%$5.8M
#5
$31.5M2816%N/A

Editas Medicine Funding

DateAmountRoundLead InvestorsReference
2017-12-07$50.0MUndisclosedMorgan StanleyArticle